Eli Lilly lowers guidance for 2021
In spite of its growing revenue and positive Trulicity sales, Eli Lilly has opted to lower its 2021 guidance, according to the firm's quarterly report for the first three months of the year.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
US pharmaceutical company Eli Lilly lowers its upper estimate for this year's income in connection with the publication of its quarterly report on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analysts lose confidence in Biogen Alzheimer's approval
For subscribers
Eli Lilly has to wait a while longer for FDA verdict
For subscribers
-go.jpg)
.jpg&w=384&q=75)
